For instance, the Her2- targeted ADC ado-trastuzumab emtansine is a relatively safe FDA approved therapeutic, while a PE38-based immunotoxin targeting Her2 caused fatal on-target off-tumor hepatic toxicity during Phase 1 evaluation [106]. Here, ERBB2 is linked to neoplasm.